Human Herpesvirus 6B in the Transplant Recipient: When to Worry, When to Act

J Pediatric Infect Dis Soc. 2018 Dec 26;7(suppl_2):S75-S78. doi: 10.1093/jpids/piy111.

Abstract

Human herpesvirus 6B (HHV-6B) is a ubiquitous pathogen that infects most individuals before the age of three years. HHV-6B reactivates in approximately 40% of transplant recipients where it has been associated with a number of important outcomes, especially in allogeneic transplant recipients. This article will review the epidemiology, clinical manifestations, diagnosis, and treatment of HHV-6B infection.

Publication types

  • Review

MeSH terms

  • Antiviral Agents / therapeutic use
  • Encephalitis, Viral / diagnosis*
  • Encephalitis, Viral / drug therapy*
  • Encephalitis, Viral / epidemiology
  • Encephalitis, Viral / virology
  • Foscarnet / therapeutic use
  • Ganciclovir / therapeutic use
  • Herpesvirus 6, Human* / physiology
  • Humans
  • Roseolovirus Infections / diagnosis*
  • Roseolovirus Infections / drug therapy*
  • Roseolovirus Infections / epidemiology
  • Transplant Recipients*
  • Virus Activation

Substances

  • Antiviral Agents
  • Foscarnet
  • Ganciclovir